John Beddies, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,127 of the $14,482 with a category attached, or 69.9%. 38 manufacturers reported payments, led by Axonics, Inc. at 36.3% of the total. Reporting peaked in 2022 at $5,206 and has fallen 83.8% since, to $842 in 2025.
Across 438 payments — averaging $33.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$5K
- Procept Biorobotics Corporation$1K
- Medtronic$1K
- Boston Scientific$973
- Olympus America Inc.$736
- Astellas Pharma US Inc$599
- plus $4K from 32 others
What the payments were for
- Travel & lodging$3,97827%
- Food & beverage$10,12770%
- Education$2442%
- Gifts$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 95 | $5,260 |
| Procept Biorobotics Corporation | 14 | $1,461 |
| Medtronic(2 entities) | 83 | $1,186 |
| Boston Scientific | 28 | $973 |
| Olympus America Inc. | 13 | $736 |
| Astellas Pharma US Inc | 30 | $599 |
| Endo Pharmaceuticals Inc. | 24 | $475 |
| AbbVie(2 entities) | 28 | $408 |
| Sumitomo Pharma America, Inc. | 15 | $367 |
| Pfizer | 12 | $328 |
| Dendreon Pharmaceuticals LLC | 7 | $298 |
| Caldera Medical, Inc | 6 | $280 |
| Coloplast | 11 | $248 |
| Teleflex LLC | 7 | $228 |
| Urogen Pharma, Inc. | 7 | $181 |
| Endo USA, Inc. | 8 | $176 |
| Johnson & Johnson | 4 | $146 |
| Urovant Sciences Inc | 8 | $136 |
| Bayer | 5 | $101 |
| Myriad Genetic Laboratories, Inc. | 4 | $85 |
| Photocure Inc | 2 | $82 |
| Myovant Sciences Inc. | 4 | $79 |
| Neotract Inc. | 2 | $78 |
| Bard Access Systems, Inc. | 1 | $77 |
| Convatec Inc. | 3 | $66 |
| Immunitybio, Inc. | 2 | $59 |
| Tolmar, Inc. | 2 | $50 |
| Angiodynamics, Inc. | 1 | $49 |
| Merck | 2 | $42 |
| Calyxo, Inc. | 2 | $37 |
| Fujifilm New Development USA, Inc. | 1 | $34 |
| Blue Earth Diagnostics | 1 | $32 |
| Valencia Technologies Corporation | 1 | $28 |
| 180 Medical, Inc. | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| ABC Home Medical Supply, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bulkamid$3,429
- Axonics$904
- AQUABEAM SYSTEM$600
- AquaBeam Robotic System$492
- INTERSTIM$131
- UPSYLON$128
- SpaceOAR VUE System - 10mL$115
- XTANDI$110
- PROVENGE$107
- iTIND System$106
- Solyx SIS System$102
How this compares
$14,482 in reported general payments places this provider in the 80th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 84 | $74,047 |
| MyrbetriqMirabegron | 46 | $31,427 |
| Tamsulosin Hcl | 930 | $10,713 |
| Oxybutynin Chloride ErOxybutynin Chloride | 244 | $5,952 |
| Finasteride | 376 | $5,883 |
| Solifenacin Succinate | 87 | $5,122 |
| Trimethoprim | 38 | $2,204 |
| Darifenacin ErDarifenacin Hydrobromide | 28 | $1,751 |
| Testosterone Cypionate | 46 | $1,677 |
| Potassium Citrate ErPotassium Citrate | 18 | $1,555 |
| Oxybutynin Chloride | 139 | $1,482 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 61 | $1,090 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,081 |
| Dutasteride | 25 | $664 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 27 | $617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $367 | $74,04784 claims |
| Astellas Pharma US IncMyrbetriq | $599 | $31,42746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 276 urology providers in Tennessee.
Other urology in Paris
- Joe MobleyParis$18K
- L KnollNashville$2.1M
- David GubinMemphis$1M
- Gautam JayramNashville$1M
- David MorrisHendersonville$871K
- Roger DmochowskiNashville$763K
- Paul EberGermantown$476K
- Ashley TapscottNashville$425K
- Raoul ConcepcionNashville$339K
- Melissa KaufmanNashville$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.